JP2009519995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519995A5 JP2009519995A5 JP2008546405A JP2008546405A JP2009519995A5 JP 2009519995 A5 JP2009519995 A5 JP 2009519995A5 JP 2008546405 A JP2008546405 A JP 2008546405A JP 2008546405 A JP2008546405 A JP 2008546405A JP 2009519995 A5 JP2009519995 A5 JP 2009519995A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- phenyl
- alkoxy
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 12
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- WWINACYDRQWTQL-UHFFFAOYSA-N 2-pyridin-2-ylquinazoline Chemical class N1=CC=CC=C1C1=NC=C(C=CC=C2)C2=N1 WWINACYDRQWTQL-UHFFFAOYSA-N 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- -1 amino, phenyl Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 102000004257 Potassium Channel Human genes 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108020001213 potassium channel Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- VMCYVBNHQWYRIH-UHFFFAOYSA-N 2-(6-bromopyridin-2-yl)-n-(4-chlorophenyl)quinazolin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C=2N=C(Br)C=CC=2)=NC2=CC=CC=C12 VMCYVBNHQWYRIH-UHFFFAOYSA-N 0.000 claims 1
- FWMJAPATBKENDT-UHFFFAOYSA-N 2-(6-chloropyridin-2-yl)-n-cyclohexylquinazolin-4-amine Chemical compound ClC1=CC=CC(C=2N=C3C=CC=CC3=C(NC3CCCCC3)N=2)=N1 FWMJAPATBKENDT-UHFFFAOYSA-N 0.000 claims 1
- VNAXTFRAFZYSAU-UHFFFAOYSA-N 6-[4-(4-chloroanilino)quinazolin-2-yl]-1h-pyridin-2-one Chemical compound OC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=CC(Cl)=CC=3)N=2)=N1 VNAXTFRAFZYSAU-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000005946 Xerostomia Diseases 0.000 claims 1
- RSORCXPIECRCKY-UHFFFAOYSA-N [2-[4-(4-chloroanilino)quinazolin-2-yl]pyridin-3-yl]-phenylmethanone Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C=2C(=CC=CN=2)C(=O)C=2C=CC=CC=2)=NC2=CC=CC=C12 RSORCXPIECRCKY-UHFFFAOYSA-N 0.000 claims 1
- HTSYTHDIUMCBKH-UHFFFAOYSA-N [2-[4-(cyclohexylamino)quinazolin-2-yl]pyridin-3-yl]-phenylmethanone Chemical compound C=1C=CN=C(C=2N=C3C=CC=CC3=C(NC3CCCCC3)N=2)C=1C(=O)C1=CC=CC=C1 HTSYTHDIUMCBKH-UHFFFAOYSA-N 0.000 claims 1
- VGAFSQIQASKIOO-UHFFFAOYSA-N [2-[4-[(4-chlorophenyl)methylamino]quinazolin-2-yl]pyridin-3-yl]-phenylmethanone Chemical compound C1=CC(Cl)=CC=C1CNC1=NC(C=2C(=CC=CN=2)C(=O)C=2C=CC=CC=2)=NC2=CC=CC=C12 VGAFSQIQASKIOO-UHFFFAOYSA-N 0.000 claims 1
- 230000006578 abscission Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- FTKDZDBBQCZTNT-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(6-chloropyridin-2-yl)quinazolin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C=2N=C(Cl)C=CC=2)=NC2=CC=CC=C12 FTKDZDBBQCZTNT-UHFFFAOYSA-N 0.000 claims 1
- BRTAGQDKNYLLAG-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(6-fluoropyridin-2-yl)quinazolin-4-amine Chemical compound FC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=CC(Cl)=CC=3)N=2)=N1 BRTAGQDKNYLLAG-UHFFFAOYSA-N 0.000 claims 1
- MXHVEOPSTJRGMD-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(6-methoxypyridin-2-yl)quinazolin-4-amine Chemical compound COC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=CC(Cl)=CC=3)N=2)=N1 MXHVEOPSTJRGMD-UHFFFAOYSA-N 0.000 claims 1
- NTEWOZTXRXEMHX-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(6-methylpyridin-2-yl)quinazolin-4-amine Chemical compound CC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=CC(Cl)=CC=3)N=2)=N1 NTEWOZTXRXEMHX-UHFFFAOYSA-N 0.000 claims 1
- VFPROCIHGMCXHH-UHFFFAOYSA-N n-(4-chlorophenyl)-2-isoquinolin-1-ylquinazolin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1=NC(C=2C3=CC=CC=C3C=CN=2)=NC2=CC=CC=C12 VFPROCIHGMCXHH-UHFFFAOYSA-N 0.000 claims 1
- WFDQFBQJVNTTIE-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-(6-chloropyridin-2-yl)quinazolin-4-amine Chemical compound C1=CC(Cl)=CC=C1CNC1=NC(C=2N=C(Cl)C=CC=2)=NC2=CC=CC=C12 WFDQFBQJVNTTIE-UHFFFAOYSA-N 0.000 claims 1
- UMYHCFBBHYJGDG-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-(6-methylpyridin-2-yl)quinazolin-4-amine Chemical compound CC1=CC=CC(C=2N=C3C=CC=CC3=C(NCC=3C=CC(Cl)=CC=3)N=2)=N1 UMYHCFBBHYJGDG-UHFFFAOYSA-N 0.000 claims 1
- QYEQWOGYFKRXSB-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-isoquinolin-1-ylquinazolin-4-amine Chemical compound C1=CC(Cl)=CC=C1CNC1=NC(C=2C3=CC=CC=C3C=CN=2)=NC2=CC=CC=C12 QYEQWOGYFKRXSB-UHFFFAOYSA-N 0.000 claims 1
- ZKKHVHRNPYCPTF-UHFFFAOYSA-N n-cyclohexyl-2-(6-methylpyridin-2-yl)quinazolin-4-amine Chemical compound CC1=CC=CC(C=2N=C3C=CC=CC3=C(NC3CCCCC3)N=2)=N1 ZKKHVHRNPYCPTF-UHFFFAOYSA-N 0.000 claims 1
- AEOLKKPUMHKDHH-UHFFFAOYSA-N n-cyclohexyl-2-isoquinolin-1-ylquinazolin-4-amine Chemical compound C1CCCCC1NC1=NC(C=2C3=CC=CC=C3C=CN=2)=NC2=CC=CC=C12 AEOLKKPUMHKDHH-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200501801 | 2005-12-20 | ||
| US75203605P | 2005-12-21 | 2005-12-21 | |
| PCT/EP2006/069795 WO2007071632A2 (en) | 2005-12-20 | 2006-12-18 | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009519995A JP2009519995A (ja) | 2009-05-21 |
| JP2009519995A5 true JP2009519995A5 (https=) | 2010-01-28 |
Family
ID=37930374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546405A Abandoned JP2009519995A (ja) | 2005-12-20 | 2006-12-18 | 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての２−ピリジン−２−イル−キナゾリン誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20090306102A1 (https=) |
| EP (1) | EP1966184B1 (https=) |
| JP (1) | JP2009519995A (https=) |
| WO (1) | WO2007071632A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010502674A (ja) * | 2006-09-07 | 2010-01-28 | ノイロサーチ アクティーゼルスカブ | カリウムチャンネル調節剤として有用なピリジニル−ピリミジン誘導体 |
| CA2665398A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
| JP2010517970A (ja) * | 2007-02-02 | 2010-05-27 | ノイロサーチ アクティーゼルスカブ | ピリジニル−ピラゾール誘導体及びカリウムチャネル調節剤としてのそれらの使用 |
| EP2132208A1 (en) * | 2007-03-28 | 2009-12-16 | NeuroSearch AS | Purinyl derivatives and their use as potassium channel modulators |
| JP2010522719A (ja) * | 2007-03-28 | 2010-07-08 | ノイロサーチ アクティーゼルスカブ | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| WO2009037247A1 (en) | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| CN101531638B (zh) * | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| CN102177154A (zh) * | 2008-09-02 | 2011-09-07 | 神经研究公司 | 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用 |
| WO2010034707A1 (en) | 2008-09-26 | 2010-04-01 | Neurosearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| EP2344501A1 (en) * | 2008-09-26 | 2011-07-20 | NeuroSearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| NZ596546A (en) * | 2009-05-29 | 2012-12-21 | Syngenta Participations Ag | Substituted quinazolines as fungicides |
| SMT201700026T1 (it) | 2009-09-03 | 2017-03-08 | Bristol Myers Squibb Co | Chinazoline come inibitori dei canali degli ioni potassio |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| WO2012016081A2 (en) * | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Method and therapeutic for the treatment and regulation of memory formation |
| WO2012069652A2 (en) * | 2010-11-26 | 2012-05-31 | Syngenta Participations Ag | Fungicide mixtures |
| JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| CA2876780A1 (en) | 2012-06-26 | 2014-01-03 | Saniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
| US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
| US9585396B2 (en) | 2013-01-30 | 2017-03-07 | Agrofresh Inc. | Volatile applications against pathogens |
| US9138001B2 (en) | 2013-01-30 | 2015-09-22 | Agrofresh Inc. | Use of benzoxaboroles as volatile antimicrobial agents on meats, plants, or plant parts |
| US8669207B1 (en) | 2013-01-30 | 2014-03-11 | Dow Agrosciences, Llc. | Compounds and compositions |
| JP2018525345A (ja) | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| WO2017155879A1 (en) | 2016-03-07 | 2017-09-14 | Agrofresh Inc. | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops |
| AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
| PL3571193T3 (pl) | 2017-01-23 | 2022-04-25 | Cadent Therapeutics, Inc. | Modulatory kanału potasowego |
| SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| EP3870291A1 (en) | 2018-10-22 | 2021-09-01 | Cadent Therapeutics, Inc. | Crystalline forms of potassium channel modulators |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| UY40234A (es) | 2022-04-22 | 2023-11-15 | Vertex Pharma | Compuestos heteroarilo para el tratamiento del dolor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE37183T1 (de) * | 1983-09-29 | 1988-09-15 | Akzo Nv | Chinazolin- und isochinolin-derivate. |
| JP2657760B2 (ja) * | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | ４−アミノキナゾリン誘導体およびそれを含有する医薬品 |
| JPH083144A (ja) * | 1994-06-21 | 1996-01-09 | Chugai Pharmaceut Co Ltd | キナゾリン及びキノリン誘導体 |
| JP2008526734A (ja) * | 2004-12-31 | 2008-07-24 | エスケー ケミカルズ カンパニー リミテッド | 糖尿及び肥満治療予防に有効なキナゾリン誘導体 |
| US20090036475A1 (en) * | 2005-03-22 | 2009-02-05 | Neurosearch A/S | Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use |
| EP1863796A1 (en) | 2005-03-22 | 2007-12-12 | NeuroSearch A/S | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
-
2006
- 2006-12-18 US US12/095,281 patent/US20090306102A1/en not_active Abandoned
- 2006-12-18 JP JP2008546405A patent/JP2009519995A/ja not_active Abandoned
- 2006-12-18 WO PCT/EP2006/069795 patent/WO2007071632A2/en not_active Ceased
- 2006-12-18 EP EP06841392A patent/EP1966184B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519995A5 (https=) | ||
| JP2010505794A5 (https=) | ||
| JP2010502674A5 (https=) | ||
| JP2008534472A5 (https=) | ||
| CN103917525B (zh) | Lrrk2激酶活性的抑制剂 | |
| JP2010522718A5 (https=) | ||
| JP6522682B2 (ja) | 治療用化合物、及び関連する使用の方法 | |
| DK2521549T3 (en) | Therapeutic compounds and related methods of use thereof | |
| JP6847458B2 (ja) | 抗真菌化合物のプロセス | |
| JP2018534326A5 (https=) | ||
| SK155596A3 (en) | Corticotropin releasing factor antagonists | |
| JP2009519995A (ja) | 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての２−ピリジン−２−イル−キナゾリン誘導体 | |
| JP2008533087A5 (https=) | ||
| TW201311660A (zh) | 治療性化合物及相關使用方法 | |
| JP2010520264A5 (https=) | ||
| JP2020506895A (ja) | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 | |
| HK1217945A1 (zh) | 作爲pde4亚型抑制剂用於治疗cns和其他病症的氮杂苯并咪唑化合物 | |
| JP7114591B2 (ja) | Ｇｓｋ－３阻害剤 | |
| US20230165854A1 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
| JP2017515845A5 (https=) | ||
| CN103889978A (zh) | 用于制备异噁唑基-甲氧基-烟酸的方法 | |
| JP2016525111A (ja) | ４‐（３‐シアノフェニル）‐６‐ピリジニルピリミジンｍｇｌｕ５修飾剤 | |
| US9820989B2 (en) | Method of treating conditions with kinase inhibitors | |
| US8889870B2 (en) | Kinase inhibitors | |
| JP2013534255A5 (https=) |